( Safety Efficacy and Markers Demonstrat...)Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer,Study Presented at ASCO,Health

ROCKVILLE, Md., June 06, 2007 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics primarily for the treatment of cancer and inflammatory diseases, announced the presentation of interim data from the Phase 1b study with Panzem(R) NCD (2ME2 or 2-methoxyestradiol) in combination with Taxol(R) (paclitaxel) in patients with metastatic breast cancer. The study is being conducted at the Duke University Medical Center under a grant from the Susan G. Komen Breast Cancer Foundation. Kimberly L. Blackwell, M.D., Director, Clinical Trials in Breast Cancer at the Duke University Medical Center, and principal investigator presented the data during a podium presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting this week in Chicago, Illinois.

The primary objective of the study was to evaluate the effects of standard chemotherapy (paclitaxel) alone and in combination with the antiangiogenic drug, 2-methoxyestradiol, on biomarkers of hypoxia and angiogenesis in metastatic breast cancer. Prior preclinical studies conducted by the Duke team demonstrated that inhibition of HIF-1alpha (hypoxia-inducible factor-1 alpha) caused near-complete destruction of tumor vessels and significantly improved radio-sensitivity in radiation resistant breast tumors. The inhibition of HIF-1alpha was thought to have the same or similar impact on chemotherapy-resistant tumors. HIF-1alpha is over-expressed in more than 70% of human tumors and HIF-1alpha over-expression correlates with tumor aggressiveness, metastases and poor prognosis.

Results were presented for ten patients with clinical stage IV or inoperable stage III breast cancer who received orally-administered Panzem(R) NCD in combination with Taxol(R). All ten patients received prior anthracycline therapy and nine received taxane therapy.
'"/>